Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
−Removed: common stock is currently quoted on the OTCQB Marketplace under the symbol “OPXS”.
−Removed: Trading in our common stock has historically
−Removed: lacked consistent volume, and the market price has been volatile.
−Removed: Over-the-counter market quotations reflect inter-dealer prices, without
−Removed: retail mark-up, mark-down or commission and may not necessarily represent actual transactions.
−Removed: December 16, 2022, the closing price for our common stock as reported on the OTCQB was $3.07 per share.
−Removed: December 7, 2022, the Company submitted an application to list its common stock on the NASDAQ Capital Market.
−Removed: There are no assurances
−Removed: (1) that the Company will continue to meet the initial listing criteria throughout the pendency of the application (including with respect
−Removed: to its share price), (2) that NASDAQ will approve the application or (3) relating to the timing of any such approval.
−Removed: If and when listed
−Removed: on NASDAQ, there are no assurances that the Company will continue to meet NASDAQ’s continued listing requirements.
+Added: common stock is listed on the Nasdaq Capital Market under the symbol “OPXS”.
+Added: December 15, 2023, the closing price for our common stock was $4.15 per share.
outstanding and holders of record
3 unchanged sentences
Sales of Equity Securities
−Removed: January 4, 2022, the Company issued 23,216 common shares to an officer and a key employee in settlement of 33,000 restricted stock units
−Removed: which vested on such date.
−Removed: The issuance was made pursuant to the exemption from registration afforded by Rule 506(b) under the Securities
−Removed: Act as an issuance to an accredited investors.
+Added: May 9, 2023, the Board of Directors approved a grant of 40,000 shares of restricted stock to independent board member Dayton Judd.
+Added: shares vest 50% on each of January 1, 2024 and January 1, 2025.
+Added: As of the grant date, the fair value of the shares was $124 thousand,
+Added: to be amortized on a straight-line basis through January 1, 2025.
+Added: The grant was exempt from registration under the Securities Act of
+Added: 1933, as amended, in reliance on Section 4(a)(2) of such act and Rule 506 thereunder.
Purchases of Equity Securities
−Removed: table below sets forth information with respect to purchases made by or on behalf of the Company or any “affiliated purchaser”
−Removed: (as defined in Rule 10b-18(a)(3) under the Exchange Act) of its common shares during the three months ended October 2, 2022.
−Removed: Total number of shares purchased
−Removed: Total purchase cost
−Removed: Average price paid per share (with transaction fees)
−Removed: Maximum dollar value that may yet be purchased under the plan
−Removed: July 4, 2022 through July 25, 2022 (1)
−Removed: July 26, 2022 through August 28, 2022 (1)
−Removed: August 29, 2022 to October 2, 2022 (2)
−Removed: September 22, 2021 the Company announced authorization for a $1 million stock repurchase program.
−Removed: As of October 2, 2022, there were
−Removed: zero shares held in treasury purchased under the September 2021 stock repurchase program.
−Removed: The shares authorized to be repurchased
−Removed: under the repurchase program may be purchased from time to time at prevailing market prices, through open market or in negotiated
−Removed: transactions, depending upon market conditions and subject to Rule 10b-18 as promulgated by the SEC.
−Removed: shares repurchased pursuant to the tender offer that closed on September 15, 2022.
−Removed: Total tendered shares of 1,603,773 at $2.65, or
−Removed: $4.25 million, plus transaction costs of $111 thousand.
−Removed: The repurchased shares were immediately cancelled.
+Added: were no purchases made by or on behalf of the Company or any “affiliated purchaser” (as defined in Rule 10b-18(a)(3) of its
+Added: common stock under the Exchange Act) during the three months ended October 1, 2023.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.